These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 6072779)

  • 1. Relationship of long-acting thyroid stimulator to the clinical features and course of Graves' disease.
    Lipman LM; Green DE; Snyder NJ; Nelson JC; Solomon DH
    Am J Med; 1967 Oct; 43(4):486-98. PubMed ID: 6072779
    [No Abstract]   [Full Text] [Related]  

  • 2. Relationships among immunoglobulin markers in Graves' disease.
    Ozawa Y; Maciel RM; Chopra IJ; Solomon DH; Beall GN
    J Clin Endocrinol Metab; 1979 Mar; 48(3):381-7. PubMed ID: 581874
    [No Abstract]   [Full Text] [Related]  

  • 3. Long-acting thyroid stimulator in Graves' disease.
    Sellers EA; Awad AG; Schönbaum E
    Lancet; 1970 Aug; 2(7668):335-8. PubMed ID: 4194442
    [No Abstract]   [Full Text] [Related]  

  • 4. Observations against a causal relationship between the long-acting thyroid stimulator and ophthalmopathy in Graves' disease.
    McKenzie JM; McCullagh EP
    J Clin Endocrinol Metab; 1968 Aug; 28(8):1177-82. PubMed ID: 4175472
    [No Abstract]   [Full Text] [Related]  

  • 5. [Simultaneous determination of thyrotropic hormone and long-acting thyroid stimulator in the plasma of patients with Graves' disease].
    Földes J; Gesztesi E; Takács I
    Klin Wochenschr; 1971 May; 49(9):554-7. PubMed ID: 4102376
    [No Abstract]   [Full Text] [Related]  

  • 6. [The long acting thyroid stimulator (LATS) in some thyroid diseases. Preliminary results].
    Busnardo B; Accordi F; Debiasi S
    Acta Isot (Padova); 1968 Oct; 8(2):165-79. PubMed ID: 5761578
    [No Abstract]   [Full Text] [Related]  

  • 7. The long-acting thyroid stimulatory: is it of importance in Graves' disease.
    McKenzie JM; Zakarija M; D'Amour P; Joasoo A
    N Z Med J; 1975 Jan; 81(531):18-21. PubMed ID: 165442
    [No Abstract]   [Full Text] [Related]  

  • 8. [The determination of long-acting thyroid stimulator (LATS) in thyroid diseases].
    Depisch D; Höfer R; Schatz H
    Wien Z Inn Med; 1968; 49(4):121-30. PubMed ID: 5757238
    [No Abstract]   [Full Text] [Related]  

  • 9. Graves' disease with delayed hyperthyroidism. Onset after several years of euthyroid ophthalmopathy, dermopathy, and high serum LATS.
    Chopra IJ; Solomon DH
    Ann Intern Med; 1970 Dec; 73(6):985-90. PubMed ID: 5538174
    [No Abstract]   [Full Text] [Related]  

  • 10. The long-acting thyroid stimulator and the result of I 131 treatment for thyrotoxicosis.
    Martin FI; Larkins RG; Alford FP; Andrews JT; Greenberg PB; Melick RA; Penington JS
    Aust N Z J Med; 1972 May; 2(2):168-72. PubMed ID: 4116447
    [No Abstract]   [Full Text] [Related]  

  • 11. L.A.T.S. and Graves' disease.
    Hedley AJ; Ross IP; Crooks J
    Lancet; 1970 Aug; 2(7670):468-9. PubMed ID: 4195146
    [No Abstract]   [Full Text] [Related]  

  • 12. [Hyperthyroidism and the "long acting thyroid stimulator" (LATS)].
    Studer H
    Schweiz Med Wochenschr; 1967 May; 97(19):622-3. PubMed ID: 5632362
    [No Abstract]   [Full Text] [Related]  

  • 13. Correlation of long-acting thyroid stimulator with serum levels of tri-iodothyronine, thyroxine and thyrotropin in Graves' disease.
    Sawhney RC; Kannan V; Rastogi GK
    J Assoc Physicians India; 1975 Feb; 23(2):111-4. PubMed ID: 1242389
    [No Abstract]   [Full Text] [Related]  

  • 14. [LATS and Graves' disease].
    Gordon A
    Harefuah; 1971 May; 80(10):569-70. PubMed ID: 5171988
    [No Abstract]   [Full Text] [Related]  

  • 15. The long-acting thyroid stimulator of Graves' disease.
    Burke G
    Am J Med; 1968 Sep; 45(3):435-50. PubMed ID: 4876801
    [No Abstract]   [Full Text] [Related]  

  • 16. [Standardization of the radiobiological method for determination of long-acting thyroid stimulator (LATS) in human serum].
    Muramoto E; Nicolau W; Ikeda E; de Assis LM; Pieroni RR
    AMB Rev Assoc Med Bras; 1972 Oct; 18(10):379-88. PubMed ID: 4539360
    [No Abstract]   [Full Text] [Related]  

  • 17. Evolution of the concept of the pathogenesis of toxic diffuse goitre (Graves' disease) and an assessment of the long-acting thyroid stimulator (L.A.T.S.).
    Hassan HA
    J Egypt Med Assoc; 1978; 61(1-2):111-20. PubMed ID: 583050
    [No Abstract]   [Full Text] [Related]  

  • 18. Long-acting thyroid stimulator (LATS) in toxic nodular goitre, toxic adenoma and Graves' disease.
    Lamberg BA; Gordin A; Viherkoski M; Kvist G
    Acta Endocrinol (Copenh); 1969 Oct; 62(2):199-209. PubMed ID: 5394703
    [No Abstract]   [Full Text] [Related]  

  • 19. [Simultaneous determination of thyreotropic hormone and long-acting thyroid stimulator in the plasma of Basedow patients].
    Földes J; Gesztesi E; Takács I
    Orv Hetil; 1970 Dec; 111(52):3067-70. PubMed ID: 4099957
    [No Abstract]   [Full Text] [Related]  

  • 20. Editorial: The latest of L.A.T.S.
    Lancet; 1974 Aug; 2(7878):443-4. PubMed ID: 4136681
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.